The Fund Grade · free · no account needed

What grade does BPAVX get?

Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.

C

Fundprints Fund Grade · as of 2026-09-01

Boston Partners All Cap Value Fund

#183 of 440 graded active funds · value · large segment peer group

The point · specialist footprint

BPAVX puts more of its book behind proven specialists than 69% of graded funds.

Bottom 20%

Bottom 40%

Middle

● Top 40%

Top 20%

beat the S&P in 22% of quarters+3.8 pts/qtr better · 43% beat rate

That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8 points per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.

2,825 graded funds · 2.7 years of filings, measured as they were published · evidence, not advice

3 funds in the same segment carry an A — members see the names and what they charge. See the alternatives →

The grade scores this fund's specialist share — the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.

Conviction exposure

27.9%

of the book in specialist-converged names

Late-stage weight

20.3%

of the book in Crowded or Fading names

Active share

86.7%

how far it strays from the index

The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.

Inside the book — top names by stage · as of 2026-09-09

Early Conviction
BKNG 1.2%AMAT 1.1%ZBRA 1%+3 locked
Consensus
BAC 2.6%JNJ 2.2%JPM 1.9%+49 locked
Emerging
CTSH 0.5%NICE 0.4%
Crowded
MDT 1.2%L 1.2%JBL 1%+12 locked
Fading
ORCL 1.5%SNY 1.3%AIG 1.2%+12 locked

We email you the day it crosses 50% crowded, and where you stand every month.

Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.

The read · what to do with it

BPAVX earns a C grade, ranking 183 of 440, with specialist investors holding about 28% of the fund. Three higher-graded peers exist in this segment worth comparing. The most striking tension here is that ORCL, AIG, and SNY are all Fading positions, meaning specialists are actively leaving those trades while the fund still carries meaningful weight in each.

Watch ORCL, AIG, and SNY closely, as specialist exits from all three suggest weakening conviction in positions totaling roughly 4% of the fund.

Note that BKNG, AMAT, and ZBRA are Early Conviction holdings, the one area where the fund appears genuinely ahead of the crowd.

Support leaving these positions

ORCL 1.5% of the fund · Fading

SNY 1.3% of the fund · Fading

MDT 1.2% of the fund · Crowded

AIG 1.2% of the fund · Fading

L 1.2% of the fund · Crowded

Where it's genuinely early

BKNG 1.2% of the fund · Early Conviction

AMAT 1.1% of the fund · Early Conviction

ZBRA 1% of the fund · Early Conviction

Read from today's disclosed book. Evidence, not advice.

The evidence base updates this week.

The specialists — not the whales — are already positioned for what comes next. Stop finding out last.

Create your free account

No card required · open the feed in 30 seconds